Zai Lab Limited (NASDAQ:ZLAB - Get Free Report) insider Frazor Titus Edmondson III sold 1,874 shares of the firm's stock in a transaction that occurred on Friday, April 4th. The stock was sold at an average price of $33.11, for a total value of $62,048.14. Following the sale, the insider now directly owns 30,375 shares of the company's stock, valued at $1,005,716.25. This represents a 5.81 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Frazor Titus Edmondson III also recently made the following trade(s):
- On Wednesday, April 2nd, Frazor Titus Edmondson III sold 4,369 shares of Zai Lab stock. The stock was sold at an average price of $35.89, for a total transaction of $156,803.41.
- On Friday, February 28th, Frazor Titus Edmondson III sold 14,544 shares of Zai Lab stock. The shares were sold at an average price of $32.98, for a total transaction of $479,661.12.
Zai Lab Trading Up 21.5 %
Shares of NASDAQ:ZLAB traded up $5.22 during trading on Friday, reaching $29.54. The stock had a trading volume of 3,044,626 shares, compared to its average volume of 822,235. The company has a market capitalization of $3.24 billion, a P/E ratio of -10.66 and a beta of 1.09. The firm's 50-day simple moving average is $32.74 and its 200 day simple moving average is $29.07. Zai Lab Limited has a one year low of $13.48 and a one year high of $39.77.
Zai Lab (NASDAQ:ZLAB - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.19). Zai Lab had a negative return on equity of 36.97% and a negative net margin of 76.14%. The firm had revenue of $109.07 million during the quarter, compared to analysts' expectations of $110.15 million. Equities research analysts forecast that Zai Lab Limited will post -2.58 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
ZLAB has been the subject of a number of research reports. Scotiabank initiated coverage on Zai Lab in a report on Friday, March 7th. They issued a "sector outperform" rating and a $55.00 price target for the company. Cantor Fitzgerald reiterated an "overweight" rating on shares of Zai Lab in a report on Thursday, March 27th. Bank of America reissued a "neutral" rating and set a $36.10 price target (up previously from $29.00) on shares of Zai Lab in a research report on Monday, March 3rd. Finally, JPMorgan Chase & Co. lifted their price objective on Zai Lab from $44.00 to $51.00 and gave the company an "overweight" rating in a report on Thursday, March 13th.
Read Our Latest Stock Report on ZLAB
Institutional Investors Weigh In On Zai Lab
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ZLAB. GF Fund Management CO. LTD. purchased a new position in shares of Zai Lab in the fourth quarter worth $29,000. Pictet Asset Management Holding SA purchased a new stake in shares of Zai Lab during the fourth quarter valued at $31,000. Barclays PLC increased its position in shares of Zai Lab by 337.6% in the 4th quarter. Barclays PLC now owns 3,702 shares of the company's stock valued at $97,000 after acquiring an additional 2,856 shares during the period. US Bancorp DE raised its stake in Zai Lab by 1,671.9% in the 4th quarter. US Bancorp DE now owns 5,865 shares of the company's stock worth $154,000 after acquiring an additional 5,534 shares during the last quarter. Finally, Jasper Ridge Partners L.P. acquired a new stake in Zai Lab during the 4th quarter worth about $210,000. 41.65% of the stock is currently owned by hedge funds and other institutional investors.
About Zai Lab
(
Get Free Report)
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.
Featured Stories
Before you consider Zai Lab, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zai Lab wasn't on the list.
While Zai Lab currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
